A Study of Ruxolitinib and Duvelisib in People With Lymphoma
Status:
Recruiting
Trial end date:
2023-08-01
Target enrollment:
Participant gender:
Summary
This study will test the safety of ruxolitinib, given at one dose that does not change, and
duvelisib, given at different doses, to find out what effects, if any, the study treatment
has on people with relapsed or refractory NK-cell or T-cell lymphoma.